Register for this Independent Satellite Symposium in Chicago

Attacking the Signal at the Switch: Unraveling the Mysteries of mTOR Inhibition in Multiple Tumor Types

Hyatt Regency Chicago
Regency Ballroom
West Tower, Gold Level
Chicago, Illinois


Thank you for your interest in this live program. Registration is closed, as the current schedule has been completed. Please email info@clinicaloptions.com for more information.

This free independent satellite symposium, led by expert faculty members, will provide a comprehensive review of the rationale for use of mTOR inhibitors and of the current and emerging roles of these agents in clinical practice for multiple tumor types, including solid tumors and hematologic malignancies.

This presentation was selected by the American Society of Clinical Oncology® as an independent educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.

Event Date Details
Friday, May 30, 2008 6:00 PM - 8:30 PM Local Time

Registration and Dinner 6:00 PM - 6:30 PM
Symposium 6:30 PM - 8:30 PM

Agenda

Welcome and Introduction
Jose Baselga, MD

What Is the Rationale for Exploring mTOR Inhibition?
George Thomas, Jr., PhD

Confirming the Role of mTORs in Oncology: Treatment of Renal Cell Carcinoma
Robert A. Figlin, MD, FACP

mTOR Inhibition in Other Solid Tumors
Matthew Kulke, MD

Clinical Application in Hematologic Malignancies: Potential of mTOR Inhibitors
Frank Giles, MD

mTOR Inhibitors in Practice: Clinical Implications and Future Considerations
Manuel Hidalgo, MD, PhD

Panel Discussion and Audience Question and Answer Session

/upload/oncology/registration/asco_mtor_imageforregpage.gif
/upload/global/providers/pim_110.gifJointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.


Educational grant provided by:

There are no fees required to participate in this educational activity.